Floatz logo

Eplontersen

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

AstraZenecaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BB

Same molecule, other indications

Eplontersen is also rated in:

Transthyretin Amyloid CardiomyopathyDormant
B
Indicative ·
60 / 100
View asset →
Healthy VolunteersDormant
CCC
Indicative ·
48 / 100
View asset →
familial visceral amyloidosisDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →